Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhaoming Li

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Oncotargets and Therapy|August 18, 2020
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three CasesLijun Du, Lei Zhang, Ling Li, et al.
Journal of Cancer Research and Clinical Oncology|July 20, 2022
The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphomaZhenchang Sun, Wenjuan Wan, Xudong Zhang, et al.
Journal of Hematology & Oncology|February 2, 2018
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphomaXin Li, Yasong Cheng, Mingzhi Zhang, et al.
Experimental Cell Research|December 27, 2017
SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphomaJiaqin Yan, Junhui Zhang, Xudong Zhang, et al.
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphomaJiaqin Yan, Junhui Zhang, Xudong Zhang, et al.
European Journal of Radiology|November 6, 2020
Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CTXingying Li, Xinli Xie, Lei Zhang, et al.
Cancer Management and Research|February 28, 2019
Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with <i>MYC</i>, <i>BCL2/BCL6</i> gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical studyQianwen Ma, Yu Chang, Ling Li, et al.
Leukemia & Lymphoma|February 14, 2015
Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphomaYingying Cui, Xin Li, Zhenchang Sun, et al.
Annals of Hematology|June 14, 2014
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patientsZhiyuan Zhou, Xiang Li, Changying Chen, et al.
Cancer Biology & Medicine|October 11, 2021
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trialJingjing Wu, Fenghua Gao, Wenhua Wang, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Oncotargets and Therapy|August 18, 2020
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three CasesLijun Du, Lei Zhang, Ling Li, et al.
Journal of Cancer Research and Clinical Oncology|July 20, 2022
The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphomaZhenchang Sun, Wenjuan Wan, Xudong Zhang, et al.
Journal of Hematology & Oncology|February 2, 2018
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphomaXin Li, Yasong Cheng, Mingzhi Zhang, et al.
Experimental Cell Research|December 27, 2017
SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphomaJiaqin Yan, Junhui Zhang, Xudong Zhang, et al.
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphomaJiaqin Yan, Junhui Zhang, Xudong Zhang, et al.
European Journal of Radiology|November 6, 2020
Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CTXingying Li, Xinli Xie, Lei Zhang, et al.
Cancer Management and Research|February 28, 2019
Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with <i>MYC</i>, <i>BCL2/BCL6</i> gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical studyQianwen Ma, Yu Chang, Ling Li, et al.
Leukemia & Lymphoma|February 14, 2015
Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphomaYingying Cui, Xin Li, Zhenchang Sun, et al.
Annals of Hematology|June 14, 2014
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patientsZhiyuan Zhou, Xiang Li, Changying Chen, et al.
Cancer Biology & Medicine|October 11, 2021
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trialJingjing Wu, Fenghua Gao, Wenhua Wang, et al.
Pageof 14